|
|
Post by mango on Sept 1, 2017 9:20:44 GMT -5
|
|
|
|
Post by mnkdfann on Sept 1, 2017 9:37:07 GMT -5
Wait, what, so Tinkerbell lied to us on the previous page?! Horrors!
(Sorta just kidding, but there's a lesson here that people should not post opinions as fact.)
|
|
|
|
Post by sayhey24 on Sept 1, 2017 9:37:33 GMT -5
Good - so now they need to change their name. Can they "get'er done" and start making some announcements and get things moving. GWPH is still trading over $100pps and they don't have what RLS has nor afrezza.
|
|
|
|
Post by slapshot on Sept 1, 2017 14:50:18 GMT -5
Wait, what, so Tinkerbell lied to us on the previous page?! Horrors! (Sorta just kidding, but there's a lesson here that people should not post opinions as fact.) Tink didn't lie, she just wasn't exactly correct in her analysis. I think the takeaway is that the name "Receptor Life Science" doesn't infringe on anyone else's trademark, which is good, but also can't be trademarked because it is too generic. Doesn't mean that the name can't be used, just that it can't be protected from others using the same or similar name. |
|
|
|
Post by nylefty on Aug 12, 2019 14:17:00 GMT -5
|
|
|
|
Post by nylefty on Aug 12, 2019 14:20:52 GMT -5
|
|
|
|
Post by brotherm1 on Aug 12, 2019 15:13:03 GMT -5
Silver Spike Acquisition Corp. Announces Pricing of $250 Million Initial Public Offering
Business Wire
Business WireAugust 7, 2019, 4:57 PM EDT
NEW YORK--(BUSINESS WIRE)--
Silver Spike Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 25,000,000 units at $10.00 per unit. The units are expected to be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “SSPKU” beginning on August 8, 2019. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the Class A ordinary shares and redeemable warrants are expected to be listed on Nasdaq under the symbols “SSPK” and “SSPKW,” respectively.
The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on businesses in the cannabis industry that are compliant with all applicable laws and regulations within the jurisdictions in which they are located or operate. The management team and board of directors are composed of veteran cannabis and finance industry executives and founders, including Scott Gordon, founder and CEO of the Company, who began investing in the cannabis industry in 2014 and in 2016 co-founded and became Chairman of Egg Rock Holdings, parent company of the Papa & Barkley family of cannabis products with related subsidiary assets in manufacturing, processing and logistics; and Dr. Orrin Devinsky, director of the Company, who is the director of the NYU Langone Comprehensive Epilepsy Center and is a Professor of Neurology, Neuroscience, Psychiatry and Neuroscience at the NYU School of Medicine and who, since 2016 has served as the Chair of the Medical Advisory Board at Tilray, a pharmaceutical and cannabis company.
|
|
|
|
Post by ryster505 on Aug 12, 2019 15:19:17 GMT -5
This could be RLS dressing istelf up to go public via SPAC merger to avoid the standard route of IPO. This is a VERY exciting development imo...
|
|
|
|
Post by seanismorris on Aug 12, 2019 16:06:34 GMT -5
This could be RLS dressing istelf up to go public via SPAC merger to avoid the standard route of IPO. This is a VERY exciting development imo... Maybe related to RLS... maybe not. The description of the listing couldn’t provide less information... but everything says SPAC. My understanding is that within 3 months we’ll find out what this is about, as they fulfill the reporting requirements of a public company. (could be wrong). There’s supposed to be a set time, to get whatever they’re doing done, but it’s not it the description. You might be able to find out more about (Silver Spike Acquisition Corp.) through: www.spacresearch.com |
|
|
|
Post by ktim on Aug 12, 2019 16:20:00 GMT -5
Wow, the cannabis craze is really that when people would be willing to invest in an IPO with no business plan other than broadly participating in cannabis market.
|
|
|
|
Post by Omega on Aug 12, 2019 16:20:46 GMT -5
From LinkedIn: Silver Spike Capital, LLC About us Silver Spike Capital is a multi-product investment manager focused on the burgeoning cannabis and related health and wellness industries. The company was formed in 2019 with an executive team consisting of seasoned investment professionals—many of whom have extensive experience in emerging and frontier markets—and cannabis industry investors and entrepreneurs with proven track records. The firm's mission is to become the leading institutional-quality asset manager in this nascent, fragmented sector. Website www.silverspikecap.comHeadquarters New York, NY CEO Scott Gordon (Mar 2019 – Present) |
|
|
|
Post by Clement on Aug 13, 2019 16:29:23 GMT -5
"On August 12, 2019, Silver Spike Acquisition Corp. (the "Company") consummated its initial public offering ("IPO") of 25,000,000 units (the "Units"). Each Unit consists of one Class A ordinary share of the Company, par value $0.0001 per share (the "Class A Ordinary Shares"), and one-half of one redeemable warrant of the Company ("Warrant"), each whole Warrant entitling the holder thereof to purchase one Class A Ordinary Share for $11.50 per share. The Units were sold at a price of $10.00 per unit, generating gross proceeds to the Company of $250,000,000. " from www.marketscreener.com/news/SILVER-SPIKE-ACQUISITION-CORP-Other-Events-Financial-Statements-and-Exhibits-form-8-K--29056179/ |
|
|
|
Post by mnholdem on Aug 13, 2019 17:15:43 GMT -5
Isn’t a key player also the CFO of Receptor?
|
|
|
|
Post by celo on Aug 13, 2019 17:26:40 GMT -5
I was going to state this same thing but I might as well quote an article: "Silver Spike has an interesting name, as do many SPACs (Hedosophia, anyone?), so a quick Google search led me to the “Nevada Silver Spike“. The “Silver Spike” was on of four ceremonial railroad ties that were driven at the connection linking the Central Pacific and the Union Pacific railroads, creating the first transcontinental railroad. The Iron Spike of the East, the Gold Spike of the West, a hybrid Iron-Silver-Gold Spike, and a Silver Spike to wed them all together. Maybe this SPAC’s name means something else entirely, but if this is the origin story, it’s rather poetic. Maybe the Silver Spike SPAC will link the entire country in a Federally legalized cannabis utopia." spacinsider.com/2019/07/22/silver-spike-acquisition-corp-files-300m-spac/Funny how they raise 250 million based on cannibis or "weed". As in it grows like a weed. Incredible, mannkind blindly scratches in the dark for pennies and these guys get 250 mill for weed. Wait, I'm an investor in Mnkd so not so funny. I guess "investment platforms" are much more advantages to invest in. If they are looking for RLS, I think Silver spike buys a majority stake and then just uses RLS or Mfannkind's inhalable device. I'm not seeing this as an RLS front to raise funds. RLS will be one spoke of many in Silver Spike's tire. |
|
|
|
Post by wsulylecoug on Aug 13, 2019 18:03:22 GMT -5
Isn’t a key player also the CFO of Receptor? RLS - CMO Orrin Devinsky, MD www.businesswire.com/news/home/20190807005852/en/Silver-Spike-Acquisition-Corp.-Announces-Pricing-250The management team and board of directors are composed of veteran cannabis and finance industry executives and founders, including Scott Gordon, founder and CEO of the Company, who began investing in the cannabis industry in 2014 and in 2016 co-founded and became Chairman of Egg Rock Holdings, parent company of the Papa & Barkley family of cannabis products with related subsidiary assets in manufacturing, processing and logistics; and Dr. Orrin Devinsky, director of the Company, who is the director of the NYU Langone Comprehensive Epilepsy Center and is a Professor of Neurology, Neuroscience, Psychiatry and Neuroscience at the NYU School of Medicine and who, since 2016 has served as the Chair of the Medical Advisory Board at Tilray, a pharmaceutical and cannabis company. |
|
